Nevertheless, because the colorectal cancer model MC38 expressed PD-L1 as well as CD200, and more complete responses were observed when both receptors were blocked, this supports the possibility that CD200 expression on tumour cells might indeed contribute to the inhibition of TIICs in vivo. This evidence concerns the gene CD200 and colorectal cancer.